Friday, July 10, 2026

pharma · Persistent Corneal Epithelial Defect (PCED) · Recent onset Type 1 Diabetes

Doppel Farmaceutici

Dompe' Farmaceutici S.p.A is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Persistent Corneal Epithelial Defect (PCED), Recent onset Type 1 Diabetes, Spastic Cerebral Palsy, C

Via Martiri delle Foibe 1, Cortemaggiore (PC), Emilia-Romagna 29016, IT, napoli HQ
1994 Founded
393 Employees
EMA registrant Type
Company details
Status
Public
HQ
Via Martiri delle Foibe 1, Cortemaggiore (PC), Emilia-Romagna 29016, IT, napoli
Founded
1994
Employees
393
Programs
11
Drugs
14
Patents
0
Clinical program

Ladarixin, Placebo to match Ladarixin

Phase 2 · small molecule · Recent onset Type 1 Diabetes

Ladarixin, Placebo to match Ladarixin for Recent onset Type 1 Diabetes is a Phase 2 program (small_molecule) at Dompe' Farmaceutici S.p.A. with 1 ClinicalTrials.gov record(s).

← All Dompe' Farmaceutici S.p.A. projects Phase 2 small molecule active

Internal code LDX0319

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Dompe' Farmaceutici S.p.A.
Phase
Phase 2
Modality
small_molecule
Indication
Recent onset Type 1 Diabetes
Status
active
Trials
1

Clinical trials